Full video transcriptClick to expand
Auto-generated transcript of @drjencaudle's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Number one, remember that these medications are not intended to be used in isolation,
- 0:05making sure that you are exercising and that you're eating a healthy diet, not just proper
- 0:09portions, but proper portions plus proper content in terms of nutrition. Making sure you're doing
- 0:15that is really important. Number two, you might simply need more time. That is right, for some
- 0:20people they need a little bit longer time than others, for these medications to really start to
- 0:25kick in and for the people to see results. So for some of us, we might just need to be patient.
- 0:31Number three, another thing I see often is the dose of your medication has not been increased.
- 0:37Remember, with many of these medications, the dose is titratable and often we do titrate it,
- 0:42which means increase the dose after so many weeks. If you're still on the first to bottom level dose,
- 0:47you may need to talk to your doctor about what other options and doses there are. Number four,
- 0:52you simply could be a non-responder. That's right, there are a certain percentage of people who
- 0:57don't really respond to these medications, meaning they lose a very small percentage of their body
- 1:01weight compared to other people who take these medications. It is possible that that is you.
- 1:07The other thing is, you know, some of these medications simply work better than others.
- 1:12Send me a message if you would like the full video on reasons why you may not be losing weight on
- 1:17ELP once.
Why you're not losing weight on GLP-1s: fact vs. TikTok
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide require dose titration over several months, and clinical trial data consistently shows that weight loss outcomes improve with higher maintenance doses alongside behavioral support. A subset of approximately 10-15% of patients in major trials do not achieve clinically significant weight loss, which is a recognized phenomenon but should be diagnosed only after ruling out inadequate dosing, poor adherence, and modifiable lifestyle factors. Patients experiencing a plateau should discuss dose adjustment, injection technique, and potential drug interactions with their prescriber before concluding they are non-responders.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Why you're not losing weight on GLP-1s: fact vs. TikTok, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Why you're not losing weight on GLP-1s: fact vs. TikTok is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Why you're not losing weight on GLP-1s: fact vs. TikTok" from DrJenCaudle. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide require dose titration over several months, and clinical trial data consistently shows that weight loss outcomes improve with higher maintenance doses alongside behavioral support.
The reason this review is not generic is the source wording and the canonical claim label "glp1 not losing weight drjencaudle fyp fyp fyp viral fypage." In this clip, the useful excerpt is: "Number one, remember that these medications are not intended to be used in isolation, making sure that you are exercising and that you're eating a healthy diet, not just proper portions, but proper portions plus proper content in terms of..." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide require dose titration over several months, and clinical trial data consistently shows that weight loss outcomes improve with higher maintenance doses alongside behavioral support.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide require dose titration over several months, and clinical trial data consistently shows that weight loss outcomes improve with higher maintenance doses alongside behavioral support. A subset of approximately 10-15% of patients in major trials do not achieve clinically significant weight loss, which is a recognized phenomenon but should be diagnosed only after ruling out inadequate dosing, poor adherence, and modifiable lifestyle factors. Patients experiencing a plateau should discuss dose adjustment, injection technique, and potential drug interactions with their prescriber before concluding they are non-responders.
- In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide produced roughly 14.9% average body weight loss when combined with behavioral counseling, not drug alone.
- Titration to maintenance dose for semaglutide takes approximately 16-20 weeks; early plateau at a starting dose is expected, not a sign of non-response.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide produced roughly 14.9% average body weight loss when combined with behavioral counseling, not drug alone.
- Titration to maintenance dose for semaglutide takes approximately 16-20 weeks; early plateau at a starting dose is expected, not a sign of non-response.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide's weight loss continued accumulating well past the 12-week mark, supporting the need for patience.
- Roughly 10-15% of GLP-1 trial participants lose less than 5% of body weight, meeting the clinical definition of non-response, but this should be the last diagnosis, not the first.
- Muscle mass loss during GLP-1 therapy can reduce resting metabolic rate and contribute to plateaus; resistance training is specifically relevant, not just generic exercise.
- Drug interactions with medications such as certain antipsychotics or corticosteroids can blunt GLP-1 effectiveness and are worth discussing with a prescriber before concluding treatment has failed.
- Injection technique errors, including inadvertent intramuscular injection instead of subcutaneous, can affect drug absorption and are an underappreciated cause of inconsistent results.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drjencaudle actually say?
In a short TikTok, Dr. Jen Caudle laid out four reasons someone might not be losing weight on a GLP-1 medication. Her list: not pairing the drug with diet and exercise, not giving it enough time, staying on too low a dose, and being a genuine non-responder. She also floated the idea that some GLP-1 medications simply "work better than others." That last point is doing a lot of work and deserves scrutiny, but the first four claims are worth taking seriously on their own terms.
This is a reasonably responsible list for a 60-second social video. None of the four reasons are invented. All of them show up in clinical literature and in real prescriber experience. The framing is calm and non-alarmist, which is more than you can say for most GLP-1 content on this platform.
Does the science back this up?
Mostly, yes. The evidence for each of her four points ranges from solid to very solid, with one important nuance on non-responders.
On lifestyle: the STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced about 14.9% body weight loss, but participants also received behavioral counseling. Studies that have isolated drug effect from behavioral intervention suggest lifestyle changes contribute meaningfully to outcomes, though the drug does most of the heavy lifting.
On time: titration schedules for semaglutide and tirzepatide run 16 to 20 weeks before patients reach maintenance doses. Expecting results at week four on 0.25 mg semaglutide is unrealistic. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide's largest weight loss effects accumulated well past the 12-week mark.
On dosing: this is well-established. Both semaglutide and tirzepatide are titrated upward precisely because higher doses produce greater weight loss. Staying at the starting dose indefinitely is not standard of care.
On non-responders: this is real, but the numbers matter. Roughly 10-15% of patients in GLP-1 trials lose less than 5% of body weight, which is considered a non-response. That is not a majority, but it is not rare either.
What did they get wrong (or right)?
She got the core framework right. These are legitimate clinical reasons for a weight loss plateau, and presenting them without panic or hype is appropriate.
Where she gets imprecise is the phrase "some of these medications simply work better than others." That is true in aggregate, but it is complicated in practice. Head-to-head data from the SURMOUNT-5 trial (2024) showed tirzepatide outperformed semaglutide on weight loss endpoints. But individual response varies considerably. Saying one drug is better without context can push patients toward switching medications when the real issue is dose, adherence, or lifestyle, not the molecule.
She also does not mention one of the more clinically relevant reasons for a plateau: loss of muscle mass during weight loss, which can lower resting metabolic rate and stall progress. Research by Bikou et al. and others has flagged this as a meaningful consideration in GLP-1 therapy. Resistance training is not just "exercise" in the generic sense she describes. It is specifically relevant here.
- Core four reasons: accurate and evidence-supported
- "Some medications work better": true but needs context to avoid driving unnecessary switching
- Muscle mass and metabolic adaptation: not mentioned, but clinically relevant
What should you actually know?
If you are on a GLP-1 and not seeing results, the checklist she offers is a reasonable starting point. But there are a few things she left out that are worth knowing before you call yourself a non-responder.
First, injection technique matters. Subcutaneous administration into muscle instead of fat can affect absorption. Second, gastrointestinal side effects sometimes lead patients to under-dose themselves without realizing it, skipping doses or delaying titration. Third, certain medications, including some antipsychotics and corticosteroids, can blunt GLP-1 effectiveness by promoting insulin resistance or increasing appetite through separate pathways.
The non-responder category is real, but it should be the last box you check, not the first. Work through dose optimization, lifestyle factors, and potential drug interactions before concluding the medication simply is not working for you. That conversation belongs with your prescriber, not a comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
DrJenCaudle · TikTok creator
80.4K views on this video
Not losing weight? #drjencaudle #fyp #fypシ #fypシ゚viral #fypage
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about in the step 1 trial (wilding et al., 2021, nejm),?
In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide produced roughly 14.9% average body weight loss when combined with behavioral counseling, not drug alone.
What does the video say about titration to maintenance dose for semaglutide takes approximately 16-20 weeks;?
Titration to maintenance dose for semaglutide takes approximately 16-20 weeks; early plateau at a starting dose is expected, not a sign of non-response.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide's weight loss?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide's weight loss continued accumulating well past the 12-week mark, supporting the need for patience.
What does the video say about roughly 10-15% of glp-1 trial participants lose less than 5%?
Roughly 10-15% of GLP-1 trial participants lose less than 5% of body weight, meeting the clinical definition of non-response, but this should be the last diagnosis, not the first.
What does the video say about muscle mass loss during glp-1 therapy can reduce resting metabolic?
Muscle mass loss during GLP-1 therapy can reduce resting metabolic rate and contribute to plateaus; resistance training is specifically relevant, not just generic exercise.
What does the video say about drug interactions with medications such as certain antipsychotics?
Drug interactions with medications such as certain antipsychotics or corticosteroids can blunt GLP-1 effectiveness and are worth discussing with a prescriber before concluding treatment has failed.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by DrJenCaudle, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.